Cytogenix News(mt) - 500 Beiträge pro Seite
eröffnet am 10.03.04 09:55:04 von
neuester Beitrag 15.03.04 18:47:48 von
neuester Beitrag 15.03.04 18:47:48 von
Beiträge: 5
ID: 832.474
ID: 832.474
Aufrufe heute: 0
Gesamt: 2.961
Gesamt: 2.961
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 39 Minuten | 1328 | |
| vor 5 Minuten | 833 | |
| gestern 18:31 | 774 | |
| heute 09:37 | 754 | |
| heute 10:47 | 737 | |
| heute 09:07 | 616 | |
| 20.04.24, 12:11 | 540 | |
| vor 5 Minuten | 531 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.161,01 | +1,36 | 217 | |||
| 2. | 3. | 0,1885 | -0,26 | 90 | |||
| 3. | 2. | 1,1800 | -14,49 | 77 | |||
| 4. | 5. | 9,3500 | +1,14 | 60 | |||
| 5. | 4. | 157,24 | -0,91 | 50 | |||
| 6. | Neu! | 0,3044 | +4,32 | 36 | |||
| 7. | Neu! | 4,7950 | +6,91 | 34 | |||
| 8. | Neu! | 11,905 | +14,97 | 31 |
Feedback
CytoGenix Awarded National Cancer Institute Research Grant for Pre-Clinical Animal Trials of Aerosol Delivered Gene Silencing Agent against Lung Tumors
Tuesday March 9, 3:43 pm ET
HOUSTON, March 9, 2004 (PRIMEZONE) -- CytoGenix, Inc. (OTC BB:CYGX.OB - News) announced that the National Cancer Institute (NCI) has awarded the company a research grant to fund the first phase of a project titled: PEI Aerosol Delivery of ssDNA Expression Vector.
ADVERTISEMENT
An aerosol compound containing the company`s single stranded DNA expression vector coded with an anti-cancer gene sequence will be tested on mice with induced metastatic lung tumors. Positive results will lead the way to further animal studies and eventually human trials.
Dr. Malcolm Skolnick, Cytogenix CEO states: ``This award is important monetarily as well as scientifically because it is granted only after competitive review by a panel of experts. We are very pleased because this enhances the company`s scientific credibility and product pipeline.``
Dr. Yin Chen, CytoGenix, Vice President of Research and Development, states: ``This delivery method to lung cells in combination with our ssDNA technology is very promising as a significant therapeutic modality for cancer and other life threatening respiratory conditions. It is non-invasive, and goes directly to airway and pulmonary surfaces, thus avoiding many of the problems associated with Intravenous or other systemic drug delivery methods that tend to cause undesirable or dangerous side effects,`` adds Dr. Chen.
CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a U.S. patent for its core DNA expression technology and has 40 international or U.S. pending patent applications.
Safe Harbor
Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at http://www.cytogenix.com.
Contact:
Communications Director
Juan Ferreira
(407) 774-9949
--------------------------------------------------------------------------------
Tuesday March 9, 3:43 pm ET
HOUSTON, March 9, 2004 (PRIMEZONE) -- CytoGenix, Inc. (OTC BB:CYGX.OB - News) announced that the National Cancer Institute (NCI) has awarded the company a research grant to fund the first phase of a project titled: PEI Aerosol Delivery of ssDNA Expression Vector.
ADVERTISEMENT
An aerosol compound containing the company`s single stranded DNA expression vector coded with an anti-cancer gene sequence will be tested on mice with induced metastatic lung tumors. Positive results will lead the way to further animal studies and eventually human trials.
Dr. Malcolm Skolnick, Cytogenix CEO states: ``This award is important monetarily as well as scientifically because it is granted only after competitive review by a panel of experts. We are very pleased because this enhances the company`s scientific credibility and product pipeline.``
Dr. Yin Chen, CytoGenix, Vice President of Research and Development, states: ``This delivery method to lung cells in combination with our ssDNA technology is very promising as a significant therapeutic modality for cancer and other life threatening respiratory conditions. It is non-invasive, and goes directly to airway and pulmonary surfaces, thus avoiding many of the problems associated with Intravenous or other systemic drug delivery methods that tend to cause undesirable or dangerous side effects,`` adds Dr. Chen.
CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a U.S. patent for its core DNA expression technology and has 40 international or U.S. pending patent applications.
Safe Harbor
Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at http://www.cytogenix.com.
Contact:
Communications Director
Juan Ferreira
(407) 774-9949
--------------------------------------------------------------------------------
Hat morchel doch schon alles gepostet!
Kurs trotzdem schon 0,65 zu 0,70
Gibt es einen längeren Thread über Cytogenix?
Gruß
Micx
Gruß
Micx
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 67 | ||
| 55 | ||
| 54 | ||
| 41 | ||
| 36 | ||
| 27 | ||
| 19 | ||
| 11 | ||
| 10 | ||
| 9 |
